VeriChip Corporation’s Healthcare Division Expands Existing Development Partnership with RECEPTORS LLC to Include New Biolo...
28 4월 2009 - 9:30PM
Business Wire
VeriChip Corporation (�VeriChip�) (NASDAQ: CHIP) and its
development partner RECEPTORS LLC, a technology company whose
AFFINITY by DESIGN� chemistry platform can be applied to the
development of selective binding products, announced today that
they are expanding their existing development partnership, beyond
the glucose-sensing RFID implantable microchip to include other
biological and environmental applications, both in combination with
RFID technology and without. The partners recently executed a
Memorandum of Understanding relating to the expansion.
In November 2008, VeriChip purchased all intellectual property
related to implantable human RFID and sensor technologies
including, but not limited to, Patent No. 7,125,382 entitled
�Embedded Bio-Sensor System� from Digital Angel Corporation. That
patent is currently being utilized in connection with VeriChip�s
and RECEPTORS� efforts to jointly develop a glucose-sensing device.
RECEPTORS recently received Patent No. 7,504,364 titled �Methods of
Making Arrays and Artificial Receptors� and Patent No. 7,469,076
�Sensors Employing Combinatorial Artificial Receptors.� RECEPTORS�
patents are currently being applied to the development of
diagnostic and sensor platforms for microbial pathogens and other
biological threats.
Scott R. Silverman, Chairman of VeriChip, said, "When VeriChip
purchased certain intellectual property from Digital Angel
Corporation in November 2008, we already envisioned the evolution
of our RFID technology from identification to biological
applications. This vision began in January 2008, when we first
partnered with RECEPTORS to develop a glucose-sensing RFID
microchip. Now, with RECEPTORS� new patents for Methods of Making
Arrays and Artificial Receptors and Sensors Employing Combinatorial
Artificial Receptors, we believe we can broadly expand these sensor
applications to many biological agents and the environment.�
About RECEPTORS LLC
RECEPTORS LLC is a private company based in Chaska, Minnesota.
RECEPTORS' mission is to advance the diagnosis and treatment of
disease and to enhance the health, safety, and quality of the
global environment through the development and application of
artificial receptor products for both research and industry. To
achieve this mission, RECEPTORS focuses its individual and
collective efforts, its commitment to excellence, and the power of
its technology to develop innovative solutions that meet the unique
needs of its customers and stakeholders. For further information
please visit http://www.receptorsllc.com.
About VeriChip
VeriChip Corporation, headquartered in Delray Beach, Florida,
has developed the VeriMed� Health Link System for rapidly and
accurately identifying people who arrive in an emergency room and
are unable to communicate. This system uses the first
human-implantable passive RFID microchip, cleared for medical use
in October 2004 by the United States Food and Drug Administration.
To complement its healthcare division, VeriChip Corporation
established VeriGreen Energy Corporation in March 2009 to focus and
invest in the clean and alternative energy sector.
For more information on VeriChip, please call 1-800-970-2447, or
e-mail info@verichipcorp.com. Additional information can be found
online at www.verichipcorp.com.
Statements about VeriChip�s future expectations, including its
ability to develop and market a glucose-sensing microchip in
conjunction with its development partner RECEPTORS LLC, its ability
to expand its development partnership with RECEPTORS LLC to include
other biological and environmental applications, and the ability of
the biological and environmental applications that are to be
jointly developed and marketed by it and RECEPTORS LLC to detect,
among other things, swine flu proteins and other proteins, and all
other statements in this press release other than historical facts
are �forward-looking statements� within the meaning of Section 27A
of the Securities Act of 1933, Section 21E of the Securities
Exchange Act of 1934, and as that term is defined in the Private
Litigation Reform Act of 1995. Such forward-looking statements
involve risks and uncertainties and are subject to change at any
time, and VeriChip�s actual results could differ materially from
expected results. Additional information about these and other
factors that could affect the Company�s business is set forth in
the Company�s various filings with the Securities and Exchange
Commission, including those set forth in the Company�s 10-K filed
on February 12, 2009, under the caption �Risk Factors.� The Company
undertakes no obligation to update or release any revisions to
these forward-looking statements to reflect events or circumstances
after the date of this statement or to reflect the occurrence of
unanticipated events, except as required by law.
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Verichip (MM) (NASDAQ:CHIP)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
